Literature DB >> 21389081

CGG-repeat length threshold for FMR1 RNA pathogenesis in a cellular model for FXTAS.

Gry Hoem1, Christopher R Raske, Dolores Garcia-Arocena, Flora Tassone, Eleonora Sanchez, Anna L Ludwig, Christine K Iwahashi, Madhur Kumar, Jane E Yang, Paul J Hagerman.   

Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder that affects carriers of premutation alleles (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene. The presence of elevated levels of expanded mRNA found in premutation carriers is believed to be the basis for the pathogenesis in FXTAS, but the exact mechanisms by which the mRNA causes toxicity are not known. In particular, it is not clear whether there is a threshold for a CGG-repeat number below which no cellular dysregulation occurs, or whether toxicity depends on mRNA concentration. We have developed a doxycycline-inducible episomal system that allows us to study separately the effects of CGG-repeat number and mRNA concentration (at fixed CGG-repeat length) in neuroblastoma-derived SK cells. Our findings show that there is a CGG-repeat size threshold for toxicity that lies between 62 and 95 CGG repeats. Interestingly, for repeat sizes of 95 CGG and above, there is a clear negative correlation between mRNA concentration and cell viability. Taken together, our results provide evidence for an RNA-toxicity model with primary dependence on CGG-repeat size and secondary dependence on mRNA concentration, thus formally ruling out any simple titration model that operates in the absence of either protein-binding cooperativity or some form of length-dependent RNA structural transition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389081      PMCID: PMC3090194          DOI: 10.1093/hmg/ddr101

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  52 in total

1.  A DNA damage checkpoint response in telomere-initiated senescence.

Authors:  Fabrizio d'Adda di Fagagna; Philip M Reaper; Lorena Clay-Farrace; Heike Fiegler; Philippa Carr; Thomas Von Zglinicki; Gabriele Saretzki; Nigel P Carter; Stephen P Jackson
Journal:  Nature       Date:  2003-11-05       Impact factor: 49.962

2.  The fragile X syndrome repeats form RNA hairpins that do not activate the interferon-inducible protein kinase, PKR, but are cut by Dicer.

Authors:  Vaishali Handa; Tapas Saha; Karen Usdin
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

3.  Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.

Authors:  F Tassone; R J Hagerman; A K Taylor; L W Gane; T E Godfrey; P J Hagerman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

4.  Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators.

Authors:  Stefania Lamartina; Giuseppe Roscilli; Cira Daniela Rinaudo; Elisabetta Sporeno; Luisa Silvi; Wolfgang Hillen; Hermann Bujard; Riccardo Cortese; Gennaro Ciliberto; Carlo Toniatti
Journal:  Hum Gene Ther       Date:  2002-01-20       Impact factor: 5.695

5.  The (CGG)n repeat element within the 5' untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter.

Authors:  Li-Sheng Chen; Flora Tassone; Parminder Sahota; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2003-09-30       Impact factor: 6.150

6.  Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers.

Authors:  C M Greco; R J Hagerman; F Tassone; A E Chudley; M R Del Bigio; S Jacquemont; M Leehey; P J Hagerman
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

7.  Clinical features of boys with fragile X premutations and intermediate alleles.

Authors:  Monica Aziz; Eleni Stathopulu; Maria Callias; Catherine Taylor; Jeremy Turk; Ben Oostra; Rob Willemsen; Mike Patton
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2003-08-15       Impact factor: 3.568

8.  RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila.

Authors:  Peng Jin; Daniela C Zarnescu; Fuping Zhang; Christopher E Pearson; John C Lucchesi; Kevin Moses; Stephen T Warren
Journal:  Neuron       Date:  2003-08-28       Impact factor: 17.173

Review 9.  The FMR1 gene and fragile X-associated tremor/ataxia syndrome.

Authors:  J R Brouwer; R Willemsen; B A Oostra
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-09-05       Impact factor: 3.568

10.  Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations.

Authors:  Beatrice Primerano; Flora Tassone; Randi J Hagerman; Paul Hagerman; Francesco Amaldi; Claudia Bagni
Journal:  RNA       Date:  2002-12       Impact factor: 4.942

View more
  37 in total

1.  Differential sensitivity to life stress in FMR1 premutation carrier mothers of children with fragile X syndrome.

Authors:  Marsha Mailick Seltzer; Erin T Barker; Jan S Greenberg; Jinkuk Hong; Christopher Coe; David Almeida
Journal:  Health Psychol       Date:  2011-12-12       Impact factor: 4.267

2.  FXTAS in an unmethylated mosaic male with fragile X syndrome from Chile.

Authors:  L Santa María; A Pugin; M A Alliende; S Aliaga; B Curotto; T Aravena; H-T Tang; G Mendoza-Morales; R Hagerman; F Tassone
Journal:  Clin Genet       Date:  2013-10-13       Impact factor: 4.438

Review 3.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

4.  Methadone use in a male with the FMRI premutation and FXTAS.

Authors:  Zukhrofi Muzar; Reymundo Lozano; Andrea Schneider; Patrick E Adams; Sultana M H Faradz; Flora Tassone; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2015-04-21       Impact factor: 2.802

5.  Calcium dysregulation and Cdk5-ATM pathway involved in a mouse model of fragile X-associated tremor/ataxia syndrome.

Authors:  Gaëlle Robin; José R López; Glenda M Espinal; Susan Hulsizer; Paul J Hagerman; Isaac N Pessah
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 6.150

6.  Ovarian abnormalities in a mouse model of fragile X primary ovarian insufficiency.

Authors:  Gloria E Hoffman; Wei Wei Le; Ali Entezam; Noriyuki Otsuka; Zhi-Bin Tong; Lawrence Nelson; Jodi A Flaws; John H McDonald; Sanjeeda Jafar; Karen Usdin
Journal:  J Histochem Cytochem       Date:  2012-04-02       Impact factor: 2.479

Review 7.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

8.  Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo.

Authors:  Renate K Hukema; Ronald A M Buijsen; Chris Raske; Lies Anne Severijnen; Ingeborg Nieuwenhuizen-Bakker; Michelle Minneboo; Alex Maas; Rini de Crom; Johan M Kros; Paul J Hagerman; Robert F Berman; Rob Willemsen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Influence of the fragile X mental retardation (FMR1) gene on the brain and working memory in men with normal FMR1 alleles.

Authors:  Jun Yi Wang; David Hessl; Christine Iwahashi; Katherine Cheung; Andrea Schneider; Randi J Hagerman; Paul J Hagerman; Susan M Rivera
Journal:  Neuroimage       Date:  2012-10-12       Impact factor: 6.556

Review 10.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.